Breast Adenocarcinoma Clinical Trial
Official title:
Immune Response to Anti-HER2 Therapies
Verified date | January 2024 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from this study may help researchers better understand the relation between cell response and anti-HER2 therapies.
Status | Recruiting |
Enrollment | 750 |
Est. completion date | July 27, 2028 |
Est. primary completion date | July 27, 2027 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age >= 18 years - Histological confirmed adenocarcinoma of the breast stage I-IV from the American Joint Committee on Cancer staging 8th edition - Any estrogen receptor (ER) or progesterone receptor (PR) but HER2 positive defined as per the most current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline - Provide written informed consent - Willingness to provide blood samples for correlative research purposes - BLOOD AND TISSUE COHORT: Scheduled to start new anti-HER2 therapy/therapies - TISSUE-ONLY COHORT: Received or previously completed anti-HER2 therapy/therapies Exclusion Criteria: - Immunocompromised patients including patients known to be human immunodeficiency virus (HIV) positive - Receiving systemic steroid therapy or any other immunosuppressive therapy =< 30 days prior to registration. NOTE: Inhaled steroids, low-dose corticosteroids (e.g. equivalent to or less than oral prednisone 10 mg daily), and steroid use for primary prevention of nausea per institutional guidelines are allowed. |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Florida | Jacksonville | Florida |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Proportion of patients who develop HER2-specific T cell and endogenous antibody responses | A two sided alpha=0.10 test of proportions will be used to assess whether the proportion of women who develop a HER2-specific immune response differs between the women who develop a tumor response and those who do not. | Up to 16 weeks | |
Other | Levels of HER2 CD4 T-cells, HER2 CD8 T-cells, and HER2-specific antibodies | Descriptive statistics will be used to quantify T cell or antibody response within each cohort of patients, namely (neo)adjuvant vs. metastatic setting and within each anti-HER2 treatments (i.e. trastuzumab, pertuzumab, lapatinib, or neratinib). | Up to 16 weeks | |
Other | Association between combination therapy and immunity to common breast cancer associated antigens | Descriptive statistics will be used. | Up to 16 weeks | |
Other | Association between HER2-specific T cell or antibody immunity and improved progression-free survival | Descriptive statistics will be used. | Up to 16 weeks | |
Other | Association between HER2-specific T cell or antibody immunity and improved overall survival in patients | Descriptive statistics will be used. | Up to 16 weeks | |
Other | Association between anti-HER2 therapy and HER2 loss and modulation of HER2-specific adaptive immune responses | Descriptive statistics will be used. | Up to 16 weeks | |
Other | Association between loss-of-function mutations and recurrence | Descriptive statistics will be used. | Up to 16 weeks or recurrence | |
Other | Association between gene expression levels and recurrence | Descriptive statistics will be used. | Up to 16 weeks or recurrence | |
Other | Association between Fc gamma receptor (R) or human leukocyte antigen (HLA) genotypes and ability to generate immunity | Descriptive statistics will be used. | Up to 16 weeks | |
Primary | HER2 specific T-cell response and clinical response | Defined as (1) a 2-fold or greater increase in HER2-specific T cells or HER2-specific antibodies at any point during treatment if pre-treatment levels of HER2-specific T cells or antibodies are detectable, or (2) HER2-specific T cells or HER2-specific antibodies at any point during treatment if pretreatment levels of HER-2 binding activity are non-detectable. | Up to 16 weeks | |
Primary | Antibody response and clinical response | Defined as (1) a 2-fold or greater increase in HER2-specific T cells or HER2-specific antibodies at any point during treatment if pre-treatment levels of HER2-specific T cells or antibodies are detectable, or (2) HER2-specific T cells or HER2-specific antibodies at any point during treatment if pretreatment levels of HER-2 binding activity are non-detectable. | Up to 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03106415 -
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04535323 -
Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer
|
Phase 1 | |
Withdrawn |
NCT03666819 -
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
|
Phase 2 | |
Completed |
NCT03094052 -
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
|
Phase 2 | |
Not yet recruiting |
NCT01942629 -
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
|
N/A | |
Terminated |
NCT03137693 -
Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer
|
N/A | |
Active, not recruiting |
NCT00433511 -
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
|
Phase 3 | |
Active, not recruiting |
NCT01245712 -
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
|
Phase 2 | |
Completed |
NCT00005970 -
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
|
Phase 3 | |
Active, not recruiting |
NCT02115282 -
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
|
Phase 3 | |
Suspended |
NCT03432741 -
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
|
Phase 1 | |
Completed |
NCT00869206 -
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
|
Phase 3 | |
Recruiting |
NCT04300829 -
Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients
|
Phase 3 | |
Not yet recruiting |
NCT06401889 -
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
|
||
Active, not recruiting |
NCT02488967 -
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
|
Phase 3 | |
Recruiting |
NCT05447910 -
Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
|
Phase 2 | |
Terminated |
NCT02824575 -
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01730833 -
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT04857697 -
Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer
|
Early Phase 1 | |
Active, not recruiting |
NCT02957968 -
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
|
Phase 2 |